annual_slider (1) annual_slider (1)

Focus on Reimbursement, Regulation and Innovation

Register now for ACLA’s 20th Annual Meeting, May 4-5, 2015 in Washington, DC.

Register Now »
pama slider pama slider

The Protecting Access to Medicare Act of 2014

Big changes are coming to how Medicare pays for clinical lab services – here’s everything your lab needs to know about the new law. 

Learn More »

slider slider

Academic Medical Center Labs to OMB: Don’t Stifle LDT Innovation

The nation’s leading academic medical center labs have joined together to warn against further FDA regulation of laboratory developed tests.

Learn More »

img (1) img (1)

Lab Testing Highlighted at Personalized Medicine Roundtable

Dr. Frank Cockerill, director of laboratory medicine at Mayo Clinic, discusses the future of personalized medicine at a House Energy and Commerce roundtable.

Read More »
tricare slider tricare slider

TRICARE: Restore Coverage Now

TRICARE’s non-coverage of over 100 molecular diagnostic tests compromises the standard of care for our military families.

Learn More »
slider-img slider-img

Clinical Lab Cuts Have Reached a Tipping Point

Additional Medicare cuts will take away jobs, stifle innovation, and put patient access to vital lab tests at risk.

Learn More »
meeting meeting

Advocacy In Action

Our grassroots network of lab professionals and patients make all the difference when it comes to shaping smart policy in Washington.

Take Action »
centenarian centenarian

Life-Saving Medicine Starts Here

Clinical lab tests guide more than 70% of medical decisions. Lab tests save time, money, and lives by enabling early detection and prevention of disease.

Learn More »

View all news & updates » Recent News & Updates

View all news & updates »

Policy Issues

  • Reimbursement and Coverage

    Medicare cuts to clinical labs threaten jobs, stifle innovation, and put patient access to vital lab tests at risk.

    Continue Reading »

  • Laboratory Developed Tests

    FDA regulation of laboratory-developed tests (LDTs) is duplicative, outside of FDA jurisdiction, and would negatively impact patient access to vital lab tests.

    Continue Reading »

  • IOAS Exception

    Self-referral leads to over-utilization, mistreated patients, and billions of wasted Medicare dollars. It’s time to close the loophole.

    Continue Reading »

View all policy issues »